Akademik Veri Yönetim Sistemi
Kurt S. (Yürütücü)
AB Destekli Diğer Projeler, 2018 - 2019
Tinnitus can be a debilitating condition, which negatively affects a patient’s overall health and social well-being. Even moderate cases can interfere with the ability to work and socialise. The financial consequences of tinnitus are significant. Personal economic loss to an individual with tinnitus--including lost earnings, productivity, and health expenses--can be up to €30,000 annually. The cost to society as a whole has been estimated at upwards of €26 billion annually. Despite these effects there is currently no scientifically proven cure for most cases of chronic tinnitus. The search for a definitive cure is ongoing and real progress is being made, but there is currently no clinically proven way to fully eliminate the perception of tinnitus. ENT (Ear, Nose and Throat) specialists, audiologists, and electronics-biomedical engineers in GenMel Technology have developed a new, patient-specific, state-of-the-art technology and patented musical therapy system called TinniMizer as a new treatment for Tinnitus due to a substantial need to cure this condition with an easy-to-use and cost-effective therapeutic system. TinniMizer uses sound stimuli to reset back hyperactive nerve cells to their normal condition. Our preliminary results obtained from about 20 patients at three clinics indicate that after using TinniMizer system for about 3 months, there is approximately 70% reduction in the complaints of tinnitus patients. The main goal of GENMEL is to develop and bring to market new products, services and business models that could drive economic growth. We target to achieve a total turnover of >€14.5 million by the 5th year of Tinnimizer commercialization.